CD19 and B-cell non-Hodgkin lymphoma: Despite all success, it becomes evident that the plateau phase of tumor progression as seen after CD19-CAR administration for B cell lymphoma [75,76] has not been achieved in a similar fashion with BCMA-CARs in MM so far.